Clovis Oncology, Inc.
CLVS
CLVS was delisted on the 20th of December, 2022.
154 hedge funds and large institutions have $220M invested in Clovis Oncology, Inc. in 2020 Q1 according to their latest regulatory filings, with 42 funds opening new positions, 39 increasing their positions, 42 reducing their positions, and 31 closing their positions.
108% more call options, than puts
Call options by funds: $61.7M | Put options by funds: $29.6M
35% more first-time investments, than exits
New positions opened: 42 | Existing positions closed: 31
5% more funds holding
Funds holding: 147 → 154 (+7)
7% less repeat investments, than reductions
Existing positions increased: 39 | Existing positions reduced: 42
38% less capital invested
Capital invested by funds: $358M → $220M (-$138M)
50% less funds holding in top 10
Funds holding in top 10: 2 → 1 (-1)
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Goldman Sachs
New York
|
+$7.82M |
| 2 |
Susquehanna International Group
Bala Cynwyd,
Pennsylvania
|
+$7.75M |
| 3 |
SG Americas Securities
New York
|
+$4.81M |
| 4 |
CAC
Cowen and Company
New York
|
+$3.73M |
| 5 |
IC
Ikarian Capital
Dallas,
Texas
|
+$3.3M |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Capital World Investors
Los Angeles,
California
|
-$35.9M |
| 2 |
PAI
Palo Alto Investors
Palo Alto,
California
|
-$3.37M |
| 3 |
Norges Bank
Oslo,
Norway
|
-$3.27M |
| 4 |
D.E. Shaw & Co
New York
|
-$3.13M |
| 5 |
Arrowstreet Capital
Boston,
Massachusetts
|
-$2.49M |
CLVS Hedge Fund Activity: Q1 2020 in Review
154 of the 4,538 institutional investors tracked by Wall St. Rank reported a position in Clovis Oncology, Inc. (CLVS) for Q1 2020, worth a combined $220M — down 38% from $358M a quarter earlier.
Buyers outnumbered sellers: 42 funds opened new CLVS positions and 31 closed out — a net gain of 11 holders — while 39 added to existing stakes and 42 trimmed.
The largest buyer was Goldman Sachs, adding an estimated $7.82M. The largest seller was Capital World Investors, exiting entirely with an estimated $35.9M sold.
- 154 institutional investors held Clovis Oncology, Inc. (CLVS) as of Q1 2020, up from 147 in Q4 2019.
- Funds reported $220M of Clovis Oncology, Inc. stock for Q1 2020, down 38% quarter-over-quarter.
- 42 funds opened new Clovis Oncology, Inc. positions in Q1 2020 and 31 closed out, a net change of +11 holders.
- The largest Clovis Oncology, Inc. buyer in Q1 2020 was Goldman Sachs, an estimated $7.82M added.
- The largest Clovis Oncology, Inc. seller in Q1 2020 was Capital World Investors, an estimated $35.9M sold.
Based on aggregated 13F filings for Q1 2020.